1. Home
  2. OBE vs AVXL Comparison

OBE vs AVXL Comparison

Compare OBE & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Obsidian Energy Ltd.

OBE

Obsidian Energy Ltd.

HOLD

Current Price

$6.02

Market Cap

393.3M

Sector

Energy

ML Signal

HOLD

Logo Anavex Life Sciences Corp.

AVXL

Anavex Life Sciences Corp.

HOLD

Current Price

$4.01

Market Cap

397.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OBE
AVXL
Founded
1979
2004
Country
Canada
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
393.3M
397.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
OBE
AVXL
Price
$6.02
$4.01
Analyst Decision
Hold
Strong Buy
Analyst Count
1
3
Target Price
$9.00
$22.00
AVG Volume (30 Days)
303.0K
4.1M
Earning Date
10-30-2025
11-25-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$441,312,666.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.88
$2.86
52 Week High
$7.07
$14.44

Technical Indicators

Market Signals
Indicator
OBE
AVXL
Relative Strength Index (RSI) 47.56 36.99
Support Level $5.94 $3.96
Resistance Level $6.42 $4.88
Average True Range (ATR) 0.21 0.41
MACD -0.01 0.20
Stochastic Oscillator 23.30 55.44

Price Performance

Historical Comparison
OBE
AVXL

About OBE Obsidian Energy Ltd.

Obsidian Energy Ltd is an intermediate-sized oil and gas producer with strategic assets in Alberta. It operates in a single reporting segment that is exploration, development, and holding an interest in oil and natural gas properties and related production infrastructure in the Western Canada Sedimentary Basin. The company generates the majority of the revenue from the Crude oil sale.

About AVXL Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.

Share on Social Networks: